Stiefel Michael F, Heuer Gregory G, Abrahams John M, Bloom Stephanie, Smith Michelle J, Maloney-Wilensky Eileen, Grady M Sean, LeRoux Peter D
Department of Neurosurgery, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19107, USA.
J Neurosurg. 2004 Oct;101(4):594-9. doi: 10.3171/jns.2004.101.4.0594.
Nimodipine has been shown to improve neurological outcome after subarachnoid hemorrhage (SAH); the mechanism of this improvement, however, is uncertain. In addition, adverse systemic effects such as hypotension have been described. The authors investigated the effect of nimodipine on brain tissue PO2.
Patients in whom Hunt and Hess Grade IV or V SAH had occurred who underwent aneurysm occlusion and had stable blood pressure were prospectively evaluated using continuous brain tissue PO2 monitoring. Nimodipine (60 mg) was delivered through a nasogastric or Dobhoff tube every 4 hours. Data were obtained from 11 patients and measurements of brain tissue PO2, intracranial pressure (ICP), mean arterial blood pressure (MABP), and cerebral perfusion pressure (CPP) were recorded every 15 minutes. Nimodipine resulted in a significant reduction in brain tissue PO2 in seven (64%) of 11 patients. The baseline PO2 before nimodipine administration was 38.4+/-10.9 mm Hg. The baseline MABP and CPP were 90+/-20 and 84+/-19 mm Hg, respectively. The greatest reduction in brain tissue PO2 occurred 15 minutes after administration, when the mean pressure was 26.9+/-7.7 mm Hg (p < 0.05). The PO2 remained suppressed at 30 minutes (27.5+/-7.7 mm Hg [p < 0.05]) and at 60 minutes (29.7+/-11.1 mm Hg [p < 0.05]) after nimodipine administration but returned to baseline levels 2 hours later. In the seven patients in whom brain tissue PO2 decreased, other physiological variables such as arterial saturation, end-tidal CO2, heart rate, MABP, ICP, and CPP did not demonstrate any association with the nimodipine-induced reduction in PO2. In four patients PO2 remained stable and none of these patients had a significant increase in brain tissue PO2.
Although nimodipine use is associated with improved outcome following SAH, in some patients it can temporarily reduce brain tissue PO2.
尼莫地平已被证明可改善蛛网膜下腔出血(SAH)后的神经功能预后;然而,这种改善的机制尚不确定。此外,还描述了其诸如低血压等不良全身效应。作者研究了尼莫地平对脑组织氧分压(PO2)的影响。
对发生Hunt和Hess分级为IV或V级SAH且接受动脉瘤夹闭术且血压稳定的患者,采用连续脑组织PO2监测进行前瞻性评估。每4小时通过鼻胃管或多佛氏管给予尼莫地平(60毫克)。从11例患者获取数据,每15分钟记录一次脑组织PO2、颅内压(ICP)、平均动脉血压(MABP)和脑灌注压(CPP)。尼莫地平使11例患者中的7例(64%)脑组织PO2显著降低。尼莫地平给药前的基线PO2为38.4±10.9毫米汞柱。基线MABP和CPP分别为90±20和84±19毫米汞柱。给药后15分钟脑组织PO2下降最为明显,此时平均压力为26.9±7.7毫米汞柱(p<0.05)。尼莫地平给药后30分钟(27.5±7.7毫米汞柱[p<0.05])和60分钟(29.7±11.1毫米汞柱[p<0.05])时PO2仍处于抑制状态,但2小时后恢复至基线水平。在脑组织PO2降低的7例患者中,其他生理变量如动脉血氧饱和度、呼气末二氧化碳分压、心率、MABP、ICP和CPP与尼莫地平诱导的PO2降低均无关联。4例患者的PO2保持稳定,且这些患者中无一例脑组织PO2显著升高。
尽管使用尼莫地平与SAH后预后改善相关,但在一些患者中它可暂时降低脑组织PO2。